## Phylogeny  
• Member of the tyrosine-kinase (TK) group, Eph receptor family, EphB subfamily (manning2002theproteinkinase pages 3-3).  
• One of four catalytically active human EphB receptors (EphB1–EphB4) (overman2014completingthestructural pages 1-2).  
• Closest human paralogs: EPHB1, EPHB2 and EPHB4, generated by vertebrate-specific gene duplications (unknownauthors2010theephephringene pages 16-18).  
• Orthologs include mouse EphB3 and chicken EphB3, each retaining nanomolar affinity for ephrin-B3 (bergemann1998ephrinb3aligand pages 3-5).  
• Conserved across jawed vertebrates following the two early whole-genome duplication events (brunet2016wholegenomeduplications pages 6-7).  
• Invertebrate genomes such as Drosophila and Caenorhabditis contain a single Eph receptor, underscoring vertebrate expansion of the family (manning2002theproteinkinase pages 3-3).  

## Reaction Catalyzed  
ATP + [protein]-L-tyrosine ⇌ ADP + [protein]-L-tyrosine phosphate (overman2014completingthestructural pages 7-9).  

## Cofactor Requirements  
No metal-ion cofactor requirement is reported in the available sources (overman2014completingthestructural pages 7-9).  

## Substrate Specificity  
A consensus phosphorylation motif has not been defined; in vitro assays reveal a subtly altered substrate preference compared with other EphB kinases (overman2013biochemicalandbiophysical pages 9-10).  

## Structure  
Domain organisation  
• Extracellular region comprising a globular ligand-binding domain, a cysteine-rich/EGF module and two fibronectin type III repeats (unknownauthors2005structurefunctionand pages 42-45).  
• Single-pass transmembrane helix (unknownauthors2005structurefunctionand pages 42-45).  
• Cytoplasmic segment containing a juxtamembrane region with regulatory tyrosines, a protein-tyrosine-kinase domain, a sterile-α-motif (SAM) and a C-terminal PDZ-binding motif (unknownauthors2005structurefunctionand pages 45-48).  

Kinase domain crystallography  
• Crystal structure solved at 2.2 Å after introduction of the stabilising A899P mutation, which increases yield and thermostability without altering ligand binding (overman2014completingthestructural pages 2-4).  
• Classical bilobed kinase fold with a partially ordered activation loop; an activation-loop tyrosine occupies the substrate groove in the apo state, suggesting a cis-autophosphorylation mechanism (overman2014completingthestructural pages 7-9).  
• Catalytic HRD motif (Asp758–Arg762) and the invariant lysine for ATP coordination are intact, whereas the DFG motif adopts an inactive orientation in the solved structure (overman2014completingthestructural pages 7-9).  

Unique structural features  
• Hinge-region Cys717 (Gly in other EphB kinases) constricts the solvent channel and determines a distinct inhibitor profile (overman2013biochemicalandbiophysical pages 7-8, overman2014completingthestructural pages 7-9).  
• Wild-type protein exhibits temperature-dependent salting-out, a property abrogated by the A899P mutation (overman2014completingthestructural pages 7-9).  

## Regulation  
Post-translational modifications  
• Ligand-induced oligomerisation triggers trans- and cis-autophosphorylation on juxtamembrane, kinase-domain and SAM-domain tyrosines, creating SH2 docking sites (kung2016developmentofspecific pages 1-3, unknownauthors2005structurefunctionand pages 45-48).  
• Cytoplasmic phosphatase SHP2 dephosphorylates the receptor, dampening signalling output (unknownauthors2005structurefunctionand pages 42-45).  

Conformational/allosteric control  
• Higher-order clustering of receptor ectodomains and lateral Eph–Eph interactions potentiate activation (unknownauthors2005structurefunctionand pages 42-45).  
• Activation-loop positioning observed crystallographically supports internal cis-regulation prior to ligand-stimulated phosphorylation (overman2014completingthestructural pages 7-9).  

## Function  
Expression  
• Strong expression along the midline of the developing neural tube (bergemann1998ephrinb3aligand pages 2-3).  
• mRNA present in neonatal and adult central nervous system tissues, including spinal cord (zhi2012ephrinb3(ephb3) pages 4-4).  

Physiological roles  
• Cooperates with EPHB2 to guide corpus callosum and anterior commissure axons during brain development (bergemann1998ephrinb3aligand pages 2-3).  
• Facilitates adult axonal plasticity and promotes regrowth after central nervous system injury (zhi2012ephrinb3(ephb3) pages 4-4).  
• Regulates cell protrusion, migration, proliferation and fate determination in diverse cellular contexts (kung2016developmentofspecific pages 1-3, overman2013biochemicalandbiophysical pages 1-2).  

Upstream ligand  
• Binds ephrin-B3 with nanomolar affinity and displays limited interaction with other ephrin-B ligands (bergemann1998ephrinb3aligand pages 3-5).  

Signalling partners  
• Interacts with the Ras-binding adaptor AF6 (stringer2016epha3(ephreceptor pages 7-8).  
• Downstream effectors include Src-family kinases, PI3K, MAPKs, Rho-family GTPases, FAK, paxillin and p130Cas (unknownauthors2005structurefunctionand pages 42-45).  

## Inhibitors  
• Electrophilic quinazoline inhibitors form a covalent bond with Cys717, conferring potent, selective EphB3 inhibition and enabling chemoproteomic target engagement (kung2016developmentofspecific pages 1-3).  
• Broad-spectrum ATP-competitive inhibitors (CMPD1, CMPD2, Dasatinib, Afatinib, Sorafenib, Sunitinib) are less potent against EphB3; the C717G mutation restores inhibitor sensitivity (overman2013biochemicalandbiophysical pages 7-8, overman2014completingthestructural pages 7-9).  

## Other Comments  
• Dysregulated EPHB3 activity shows context-dependent roles in cancer, acting as a tumour suppressor in colon and non-small-cell lung cancer while promoting invasion in prostate cancer (kung2016developmentofspecific pages 1-3, overman2013biochemicalandbiophysical pages 1-2).  
• The availability of isozyme-selective covalent inhibitors provides a tool for mechanistic dissection of these divergent oncogenic versus tumour-suppressive functions (kung2016developmentofspecific pages 1-3).

References

1. (bergemann1998ephrinb3aligand pages 2-3): A. Bergemann, Lee Zhang, M. Chiang, R. Brambilla, R. Klein, and J. Flanagan. Ephrin-b3, a ligand for the receptor ephb3, expressed at the midline of the developing neural tube. Oncogene, 16:471-480, Jan 1998. URL: https://doi.org/10.1038/sj.onc.1201557, doi:10.1038/sj.onc.1201557. This article has 113 citations and is from a domain leading peer-reviewed journal.

2. (manning2002theproteinkinase pages 3-3): G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. The protein kinase complement of the human genome. Science, 298:1912-1934, Dec 2002. URL: https://doi.org/10.1126/science.1075762, doi:10.1126/science.1075762. This article has 10728 citations and is from a highest quality peer-reviewed journal.

3. (unknownauthors2010theephephringene pages 16-18): The Eph/ephrin gene family in the European amphioxus: an evo-devo approach

4. (bergemann1998ephrinb3aligand pages 3-5): A. Bergemann, Lee Zhang, M. Chiang, R. Brambilla, R. Klein, and J. Flanagan. Ephrin-b3, a ligand for the receptor ephb3, expressed at the midline of the developing neural tube. Oncogene, 16:471-480, Jan 1998. URL: https://doi.org/10.1038/sj.onc.1201557, doi:10.1038/sj.onc.1201557. This article has 113 citations and is from a domain leading peer-reviewed journal.

5. (brunet2016wholegenomeduplications pages 6-7): Frédéric G. Brunet, Jean-Nicolas Volff, and Manfred Schartl. Whole genome duplications shaped the receptor tyrosine kinase repertoire of jawed vertebrates. Genome Biology and Evolution, 8:1600-1613, May 2016. URL: https://doi.org/10.1093/gbe/evw103, doi:10.1093/gbe/evw103. This article has 34 citations and is from a domain leading peer-reviewed journal.

6. (kung2016developmentofspecific pages 1-3): Alvin Kung, Ying-Chu Chen, Marianne Schimpl, Feng Ni, Jianfa Zhu, Maurice Turner, Henrik Molina, Ross Overman, and Chao Zhang. Development of specific, irreversible inhibitors for a receptor tyrosine kinase ephb3. Journal of the American Chemical Society, 138:10554-10560, Aug 2016. URL: https://doi.org/10.1021/jacs.6b05483, doi:10.1021/jacs.6b05483. This article has 37 citations and is from a highest quality peer-reviewed journal.

7. (overman2013biochemicalandbiophysical pages 1-2): R. Overman, J. Debreczeni, C. Truman, M. McAlister, and T. Attwood. Biochemical and biophysical characterization of four ephb kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles. Bioscience Reports, Apr 2013. URL: https://doi.org/10.1042/bsr20130028, doi:10.1042/bsr20130028. This article has 7 citations and is from a peer-reviewed journal.

8. (overman2014completingthestructural pages 1-2): Ross C. Overman, Judit E. Debreczeni, Caroline M. Truman, Mark S. McAlister, and Teresa K. Attwood. Completing the structural family portrait of the human ephb tyrosine kinase domains. Protein Science, May 2014. URL: https://doi.org/10.1002/pro.2445, doi:10.1002/pro.2445. This article has 31 citations and is from a peer-reviewed journal.

9. (overman2014completingthestructural pages 2-4): Ross C. Overman, Judit E. Debreczeni, Caroline M. Truman, Mark S. McAlister, and Teresa K. Attwood. Completing the structural family portrait of the human ephb tyrosine kinase domains. Protein Science, May 2014. URL: https://doi.org/10.1002/pro.2445, doi:10.1002/pro.2445. This article has 31 citations and is from a peer-reviewed journal.

10. (overman2014completingthestructural pages 7-9): Ross C. Overman, Judit E. Debreczeni, Caroline M. Truman, Mark S. McAlister, and Teresa K. Attwood. Completing the structural family portrait of the human ephb tyrosine kinase domains. Protein Science, May 2014. URL: https://doi.org/10.1002/pro.2445, doi:10.1002/pro.2445. This article has 31 citations and is from a peer-reviewed journal.

11. (overman2013biochemicalandbiophysical pages 7-8): R. Overman, J. Debreczeni, C. Truman, M. McAlister, and T. Attwood. Biochemical and biophysical characterization of four ephb kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles. Bioscience Reports, Apr 2013. URL: https://doi.org/10.1042/bsr20130028, doi:10.1042/bsr20130028. This article has 7 citations and is from a peer-reviewed journal.

12. (overman2013biochemicalandbiophysical pages 9-10): R. Overman, J. Debreczeni, C. Truman, M. McAlister, and T. Attwood. Biochemical and biophysical characterization of four ephb kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles. Bioscience Reports, Apr 2013. URL: https://doi.org/10.1042/bsr20130028, doi:10.1042/bsr20130028. This article has 7 citations and is from a peer-reviewed journal.

13. (stringer2016epha3(ephreceptor pages 7-8): B. Stringer, B. Day, Jennifer K. McCarron, M. Lackmann, and A. Boyd. Epha3 (eph receptor a3). Atlas of Genetics and Cytogenetics in Oncology and Haematology, Nov 2016. URL: https://doi.org/10.4267/2042/44710, doi:10.4267/2042/44710. This article has 2 citations and is from a peer-reviewed journal.

14. (unknownauthors2005structurefunctionand pages 42-45): Structure, function and control of the EphA3 receptor tyrosine kinase

15. (unknownauthors2005structurefunctionand pages 45-48): Structure, function and control of the EphA3 receptor tyrosine kinase

16. (zhi2012ephrinb3(ephb3) pages 4-4): Xiao-dong Zhi, Ming-Min Dong, Desui Yu, Yan-song Wang, Da Huang, and G. Lv. Ephrin b3 (ephb3) receptors expressed in spinal tissue of rats with spinal cord injury. African Journal of Pharmacy and Pharmacology, Aug 2012. URL: https://doi.org/10.5897/ajpp12.410, doi:10.5897/ajpp12.410. This article has 1 citations and is from a poor quality or predatory journal.
